Tag Archives: Adaptive Biotechnologies

May 2021—Adaptive Biotechnologies Corp. launched its T-Detect COVID, a clinical T-cell–based test to identify people who have evidence of a cellular immune response against SARS-CoV-2. It uses Adaptive’s immunoSEQ technology to sequence T-cell receptors from a blood sample and identifies TCRs that the company has mapped for recognition of SARS-CoV-2 antigens.

March 1, 2021—Adaptive Biotechnologies Corp. launched its T-Detect COVID, a clinical T-cell–based test to confirm recent or prior COVID-19 infection.

Aug. 20, 2020—Adaptive Biotechnologies received FDA clearance for its ClonoSEQ assay to detect and monitor minimal residual disease in blood or bone marrow from patients with chronic lymphocytic leukemia.

November 2015—Adaptive Biotechnologies announced a publication in Science Translational Medicine on a novel technology for pairing T-cell receptor alpha and beta chain sequences at high throughput.